TOP TIERMARKET NEWSWIRE

News & sentiment

SAGIMET BIOSCIENCES Series A (SGMT) — News & AI sentiment

SAGIMET BIOSCIENCES Series A (SGMT) news roundup. 1 story in the past week, 9 over 30 days. Average 30-day sentiment is 59.3/100. Recent insider activity (SEC Form 4, 90-day window): 0 purchases totalling $0 and 2 sales totalling $3.8M — net selling of $3.8M. No congressional trade disclosures in the last 90 days. Data shown on this page is delayed 4 hours. Real-time access — including the live wire, real-time alerts, the live S&P 500 heatmap, and the AI Top Trades long/short board — is available with a Top Tier Newswire Pro subscription.

Public view, delayed 4h. For real-time news, alerts, AI sentiment and the long/short AI Top Trades board:Open in the live terminal →

24h stories

0

7d stories

1

avg sentiment 52/100

30d stories

9

avg sentiment 59.3/100

Insider net (90d)

$3.8M

0 buys · 2 sells

Congress (90d)

0

0 buys · 0 sells

SGMT news in the last 24 hours, 7 days, 30 days and 90 days

How much SGMT coverage the wire captured in each window, with the average AI sentiment across those stories. Counts are of stories that have cleared the 4-hour public delay.

Time window	SGMT stories	Avg AI sentiment	Read
Last 24 hours	0	—	no coverage
Last 7 days	1	52/100	SGMT headlines →
Last 30 days	9	59.3/100	SGMT headlines →
Last 90 days	59	52.8/100	SGMT headlines →

Latest stories on SGMT

Sagimet Biosciences Announces Participation in Upcoming Investor Conference and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire52 · neutralgeneral

5d ago

H.C. Wainwright views Sagimet dosing news as ‘incrementally positive’

The Fly58 · neutralanalyst

Oct 22

Sagimet announces dosing of first patient in AURORA study

The Fly58 · neutralproduct/pr

Oct 22

Sagimet Biosciences Highlights Progress in Acne FASN Pipeline

TipRanks58 · neutralproduct/pr

Oct 22

Sagimet Biosciences Inc. (SGMT) files 8-K

SEC 8-K50 · neutralgeneral

Oct 22

Sagimet Biosciences Announces First Patient Dosed in AURORA Phase 3 U.S. Clinical Trial of Denifanstat for Moderate to Severe Acne

StockTitan63 · neutralproduct/pr

Oct 22

Sagimet Biosciences Announces First Patient Dosed in AURORA Phase 3 U.S. Clinical Trial of Denifanstat for Moderate to Severe Acne

GlobeNewswire63 · neutralproduct/pr

Oct 22

Sagimet Biosciences: The U.S. Acne Trial Is A Replication Exercise, Not A Discovery Bet

Seeking Alpha58 · neutralproduct/pr

Oct 21

Sagimet To Present Positive Full 52-Week Results from License Partner Ascletis' Phase 3 Open-Label Extension Clinical Trial of Denifanstat in Acne and Mechanistic Data at the 2026 Fall Clinical...

Business Insider74 · bullishproduct/pr

Oct 9

Guggenheim raises Sagimet stock price target on acne drug trial

Investing.com Analyst Ratings63 · neutralanalyst

Oct 2

Sagimet Biosciences price target raised to $26 from $25 at Guggenheim

The Fly61 · neutralanalyst

Oct 2

Sagimet closes down after acne drug denifanstat data, closing of stock offering

Seeking Alpha28 · bearishgeneral

Oct 1

Sagimet Biosciences Announces Closing of Underwritten Offering of Series A Common Stock and Pre-Funded Warrants

GlobeNewswire28 · bearishgeneral

Oct 1

Cantor Fitzgerald reiterates Sagimet stock rating on acne trial data

Investing.com Analyst Ratings56 · neutralanalyst

Oct 1

Sagimet Biosciences price target raised to $38 from $33 at Oppenheimer

The Fly61 · neutralanalyst

Oct 1

Citizens cuts Sagimet Biosciences stock price target on trial data

Investing.com Analyst Ratings34 · bearishanalyst

Oct 1

Sagimet Biosciences Inc. (SGMT) Discusses 52-Week Phase 3 Data and U.S. Phase 3 Plans for Denifanstat in Moderate to Severe Acne Transcript

Seeking Alpha56 · neutralproduct/pr

Sep 30

Sagimet Biosciences Inc. (SGMT) files 8-K

SEC 8-K50 · neutralgeneral

Sep 30

Sagimet Biosciences’ China data strengthens denifanstat case, says Clear Street

The Fly63 · neutralproduct/pr

Sep 30

Oppenheimer raises Sagimet stock price target on acne trial data

Investing.com Analyst Ratings63 · neutralanalyst

Sep 30

Why is Sagimet Biosciences stock rallying today?

Investing.com Markets50 · neutralgeneral

Sep 30

SGMT Prices $115 Million Offering at $10.00 to Fund Multiple Denifanstat Milestones September 30, 2026

MarketChameleon24 · bearishgeneral

Sep 30

Sagimet Biosciences Shares Rise 12% After Denifanstat Phase 3 Acne Trial Data

InvestorsHub68 · bullishproduct/pr

Sep 30

Sagimet Raises $115M At Premium To Fund Phase 3 Acne Drug Trial – SGMT Stock Surges Pre-Market

Stocktwits News67 · bullishgeneral

Sep 30

Sagimet (SGMT) prices $115.0 million equity raise to fund Phase 3 denifanstat acne trial September 30, 2026

MarketChameleon24 · bearishgeneral

Sep 30

Open SGMT in the live Top Tier Newswire terminal for real-time stories, sentiment, insider + congress alerts, and the AI Top Trades long/short board.Start a 1-day free trial →